Navigation Links
Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
Date:5/25/2011

n with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad, BAY 86-9766 (RDEA119) and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo: http://photos.prnewswire.com/prnh/20091104/ARDEALOGO)


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and NEW YORK , July 30, ... developer of new products for oncology supportive care, announced ... , has been featured in an article on OncLive.com ... in Head and Neck Cancers."  Dr. Steve Sonis ... on the growing demand seen in the oncology community ...
(Date:7/30/2014)... 2014 /PRNewswire-iReach/ -- This is a professional and ... sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) industry. ... Heparin sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) ... report then explores global and China,s top manufacturers ... 37270-89-6) listing their product specification, capacity, production value, ...
(Date:7/30/2014)... , July 30, 2014   Medical Equipment ... have been awarded a Department of Defense (US Army) ... to supply a mobile MRI diagnostic machine and technical ... Business (WOSB) through the Small Business Administration (SBA), Medical ... the field with the latest medical diagnostic equipment. The ...
Breaking Medicine Technology:Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
... a leading provider of next generation sequencing assays ... brand name immunoSEQ, announced today it has changed ... (Logo:  http://photos.prnewswire.com/prnh/20120103/SF28632LOGO ) ... the company,s original immune profiling business as well ...
... Inc., a privately-held, commercial-stage, healthcare company focused on the ... nervous system disorders, announced today that Holger Kunze has ... and as a member of the company,s Board of ... appointed as a member of Accera,s BoD. ...
Cached Medicine Technology:Adaptive TCR Changes Name to Adaptive Biotechnologies 2Adaptive TCR Changes Name to Adaptive Biotechnologies 3Accera, Inc. Elects Industry Veteran Holger Kunze as CEO and as a Member of the Company's Board of Directors 2Accera, Inc. Elects Industry Veteran Holger Kunze as CEO and as a Member of the Company's Board of Directors 3
(Date:7/30/2014)... Decene is an alkene with the formula ... atoms with one double bond. 1-Decene enters all ... be used as a co-monomer in certain copolymers ... oxo alcohols, synthetic lubricants, synthetic fatty acids, and ... 10% customization on this report. , http://www.micromarketmonitor.com/contact/2523613387-request_for_customization.html ...
(Date:7/30/2014)... 2014 The Europe Phytochemicals & plant ... plant extracts market in Europe with analysis and forecast ... Europe is estimated to grow from around 710.18$ million ... CAGR of 8.4%, for the given period. , Browse ... extracts market report, to get an idea of the ...
(Date:7/30/2014)... diagnosed with depression as preschoolers are likely to suffer ... research shows. , Depressed preschoolers were 2.5 times more ... middle school than kids who were not depressed at ... School of Medicine in St. Louis. , Their study ... American Journal of Psychiatry . , "It,s the same ...
(Date:7/30/2014)... Bringing Disney Excellence to Central Iowa ... the Central Iowa Chapter of the Association for Talent ... renowned professional development course, “Disney’s Approach to Business Excellence,” ... world class workshop will inspire area professionals from businesses ... and satisfy customers. , “Disney 'magic' as I call ...
(Date:7/30/2014)... organs for transplants sounds like something out of a ... day make actual kidneys, livers, hearts and other organs ... journal Langmuir , scientists are reporting new understanding ... a step closer to realizing their goal of making ... and colleagues note that this idea of producing tissues ...
Breaking Medicine News(10 mins):Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3Health News:Central Iowa Chapter of ATD Hosts Exclusive Disney Institute for Central Iowa Businesses 2Health News:Central Iowa Chapter of ATD Hosts Exclusive Disney Institute for Central Iowa Businesses 3
... study finds , THURSDAY, Dec. 6 (HealthDay News) -- ... she receives surgery after a breast cancer diagnosis, U.S. ... Medical Institutions in Baltimore also found that a lengthy ... , Factors such as socioeconomic status and the cumulative ...
... 6 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) announced today ... treatment of chronic myelogenous leukemia,(CML) at the upcoming American Society ... held December 8th - 11th, 2007 in,Atlanta, Georgia., , ... listed below:, Date: ...
... 6 Arete Therapeutics Inc., a,privately-held biopharmaceutical company ... cardiovascular, inflammatory and,metabolic diseases, today announced the appointment ... "We are very pleased to welcome Don ... operational insights will be of great benefit to ...
... New Product Name Also Unveiled in Ongoing ... Dec. 6 Favrille, Inc. (Nasdaq:,FVRL), a ... treatment of cancer, announced that new data,including ... 2 clinical,trial of Specifid(TM) (formerly FavId(R)), will ...
... US Oncology, the nation,s leading,oncology services company, today ... president and chief operating officer. The appointment,becomes effective ... operating experience, combined with his work in,large diversified ... Bruce Broussard, president of US Oncology.,"His proven success ...
... Wagoner on new data showing first increase in U.S.,teen ... that the,dramatic decrease in teen pregnancy rates in the ... a screeching halt. This unwelcome,development should not come as ... success over the last decade -- the decline in ...
Cached Medicine News:Health News:Black Women Wait Longer for Breast Cancer Surgery 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 3Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 4Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 3Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 4Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 5Health News:US Oncology Appoints Glen Laschober EVP & Chief Operating Officer 2
... Amvex offers a complete line of ... and CO 2 . They are ... calibrations to best suit your application. ... specific to the gas in use, ...
... a complete line of flowmeters, available ... 2 . They are all available ... best suit your application. With color ... the gas in use, the Amvex ...
... of flowmeters, available in oxygen, air, heliox and CO ... of calibrations to best suit your application. With color ... use, the Amvex Flowmeter is a user friendly device., ... For Power Take-Off add PT to the end of ...
... complete line of flowmeters, available in oxygen, air, heliox ... a variety of calibrations to best suit your application. ... gas in use, the Amvex Flowmeter is a user ... with I. For Power Take-Off add PT to the ...
Medicine Products: